Physician profile
Katy Garner
NPI 1821330424
$2,608.34
in general payments reported to CMS, 2019-2025
32 companies · $743 in 2025
The $743 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $357 · 2023: $564 · 2024: $395 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $335.73 | 2021-2025 | Airsupra, Farxiga |
| Abbvie INC. | $288.01 | 2021-2025 | |
| Pfizer INC. | $251.59 | 2021-2025 | |
| Novo Nordisk INC | $150.41 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $146.01 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $141.99 | 2021-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $140.54 | 2024-2025 | Hetlioz, Fanapt |
| Astellas Pharma US INC | $123.15 | 2021-2025 | Veozah |
| Scilex Pharmaceuticals INC. | $85.08 | 2022 | |
| Mylan Specialty L.P. | $81.54 | 2023-2024 | Yupelri |
| Aimmune Therapeutics, INC. | $81.21 | 2025 | Zenpep |
| Dexcom, INC. | $79.80 | 2022-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $76.36 | 2023-2025 | Minimed 780g, Inceptiv, Minimed 770g |
| Alkermes, INC. | $67.58 | 2022-2024 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.89 | 2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $45.06 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $39.84 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $37.56 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $37.55 | 2024-2025 | Gvoke Hypopen |
| Amgen INC. | $37.35 | 2022 | |
| Lilly USA, LLC | $36.39 | 2021 | |
| Merck Sharp & Dohme LLC | $34.89 | 2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $28.43 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.24 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.19 | 2021 | |
| Qorumpartners | $26.13 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.21 | 2025 | Rexulti |
| Ardelyx, INC. | $24.12 | 2025 | Ibsrela |
| Abbott Laboratories | $22.55 | 2023 | Proclaim |
| Janssen Pharmaceuticals, INC | $18.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.21 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.10 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.